Jianzhong Huang

Jianzhong Huang

Auto-generated profile, based on publicly available information

Jianzhong Huang

Infectious Diseases Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in ACS Infectious Diseases
Verified
Journal Article
Open access
AOAlexandria A. Oviatt
Alexandria A. Oviatt
EGElizabeth G Gibson
Elizabeth G Gibson
JHJianzhong Huang
Jianzhong Huang
KMKaren Mattern
Karen Mattern
KNKeir C. Neuman
Keir C. Neuman
Neil OsheroffNeil Osheroff
Neil Osheroff
Antimicrobial resistance is a global threat to human health. Therefore, efforts have been made to develop new antibacterial agents that address this critical medical issue. Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial in clinical development. Recently, phase III clinical trials for gepotidacin treatment of uncomplicated urinary tract infections caused by uropathogens, including Escherichia coli, were stopped for demonstrated efficacy. Because of the clinical promise of gepotidacin, it is important to understand how the compound interacts with its cellular targets, gyrase and topoisomerase IV, from E. coli. Consequently, we determined how gyrase and topoisomerase IV mutations in amino acid residues that are involved in gepotidacin interactions affect the susceptibility of E. coli cells to the compound and characterized the effects of gepotidacin on the activities of purified wild-type and mutant gyrase and topoisomerase IV. Gepotidacin displayed well-balanced dual-targeting of gyrase and topoisomerase IV in E. coli cells, which was reflected in a similar inhibition of the catalytic activities of these enzymes by the compound. Gepotidacin induced gyrase/topoisomerase IV-mediated single-stranded, but not double-stranded, DNA breaks. Mutations in GyrA and ParC amino acid residues that interact with gepotidacin altered the activity of the compound against the enzymes and, when present in both gyrase and topoisomerase IV, reduced the antibacterial activity of gepotidacin against this mutant strain. Our studies provide insights regarding the well-balanced dual-targeting of gyrase and topoisomerase IV by gepotidacin in E. coli.

2 December 2014 in IEEE Transactions on Magnetics
Verified
Journal Article
Closed access
JHJianzhong Huang
Jianzhong Huang
LSLingyan Sun
Lingyan Sun
SJSeongwook Jeong
Seongwook Jeong
HXHaitao Xia
Haitao Xia
WTWeijun Tan
Weijun Tan
Noise-predictive filters (NPFIRs) are an effective method to improve the system performance when the noise is correlated and data dependent, such as the media noise in the magnetic recording channel. Although the known data can be used to calibrate the NPFIRs during the manufacturing stage and save them to the zone table as the default setting, when it comes to practice, live decision outputs from the channel detector or channel decoder are needed to fine-tune the NPFIR to match the real media noise statistics better. The live decision driven NPFIR calibration works as well as the known data driven mode when the operating signal-to-noise ratio (SNR) is high. However, in the low SNR region, the performance will be degraded due to: 1) the live decision outputs from the channel detector having a low quality and 2) very few codewords having converged after channel decoding so that the NPFIR does not have enough converged codewords to calibrate. In this paper, we propose two schemes to address the low SNR NPFIR calibration issues accordingly. Simulation results are provided and showed that the proposed two schemes are effective techniques to improve the system performance in low SNR region.